List of life sciences

Clarivate Global Research Report Examines Role of Research Assessment with a Review of Six Regional Systems

Retrieved on: 
Thursday, October 20, 2022

Research assessment: origins, evolution, outcomes examines the origins of research assessment, and how it works in different regions via the approaches of Australia, Canada, Germany, Hong Kong, New Zealand and the United Kingdom.

Key Points: 
  • Research assessment: origins, evolution, outcomes examines the origins of research assessment, and how it works in different regions via the approaches of Australia, Canada, Germany, Hong Kong, New Zealand and the United Kingdom.
  • It also considers the future of research assessment exercises and examines the potential of Artificial Intelligence (AI) to replace traditional peer review.
  • Jonathan Adams, Chief Scientist at the Institute for Scientific Information at Clarivate explains: "Research assessment has had major effects on institutional structures.
  • Each one demonstrates the huge potential of research data to inform management issues in research assessment and research policy and to accelerate development of the global research base.

Clarivate Global Research Report Examines Role of Research Assessment with a Review of Six Regional Systems

Retrieved on: 
Thursday, October 20, 2022

Research assessment: origins, evolution, outcomes examines the origins of research assessment, and how it works in different regions via the approaches of Australia, Canada, Germany, Hong Kong, New Zealand and the United Kingdom.

Key Points: 
  • Research assessment: origins, evolution, outcomes examines the origins of research assessment, and how it works in different regions via the approaches of Australia, Canada, Germany, Hong Kong, New Zealand and the United Kingdom.
  • It also considers the future of research assessment exercises and examines the potential of Artificial Intelligence (AI) to replace traditional peer review.
  • Jonathan Adams, Chief Scientist at the Institute for Scientific Information at Clarivate explains: "Research assessment has had major effects on institutional structures.
  • Each one demonstrates the huge potential of research data to inform management issues in research assessment and research policy and to accelerate development of the global research base.

Latham & Watkins Releases The Book of Jargon® -- Real Estate & REITs

Retrieved on: 
Wednesday, October 19, 2022

NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Latham & Watkins LLP1 is pleased to announce the launch of The Book of Jargon® — Real Estate & REITs, a comprehensive digital glossary of more than 1,000 terms developed for the business, academic, and legal communities. The easy-to-use reference tool demystifies the often complex legal and regulatory terminology, acronyms, and slang of the real estate and real estate investment trust (REIT) industry.

Key Points: 
  • NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Latham & Watkins LLP1 is pleased to announce the launch of The Book of Jargon Real Estate & REITs, a comprehensive digital glossary of more than 1,000 terms developed for the business, academic, and legal communities.
  • The easy-to-use reference tool demystifies the often complex legal and regulatory terminology, acronyms, and slang of the real estate and real estate investment trust (REIT) industry.
  • Defining terms from "abandonment" to "zoning ordinance," Latham's latest Book of Jargon renders the real estate sector's vocabulary more accessible and understandable, especially to those navigating complex legal issues in real estate transactions.
  • Latham's Real Estate Practice guides clients through complex and high-stakes real estate transactions of every kind everywhere in the world.

Exagen Announces Appointment of John Aballi as CEO

Retrieved on: 
Monday, October 17, 2022

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President.

Key Points: 
  • SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), announced today that the company has appointed John Aballi as CEO and President.
  • The Exagen Board has appointed Mr. Aballi as CEO, President, and a member of the Board.
  • I am delighted that John has agreed to lead the next phase of growth at Exagen, said Board Chair Brian Birk.
  • Im very excited to be joining Exagen as CEO, Mr. Aballi said.

Anji Pharma and Population Health Partners Enter into Strategic Collaboration to Jointly Address High Prevalence Human Disease

Retrieved on: 
Wednesday, October 19, 2022

Anji Pharmaceuticals and Population Health Partners today announced that they have entered into a strategic collaboration, bringing together two complementary teams to jointly address high prevalence human diseases.

Key Points: 
  • Anji Pharmaceuticals and Population Health Partners today announced that they have entered into a strategic collaboration, bringing together two complementary teams to jointly address high prevalence human diseases.
  • Anji is progressing high potential late-stage clinical assets in Phase II and Phase III development.
  • Locust Walk serves as an advisor to Anji and will work in concert with Anji and PHP to further the goals of the strategic collaboration.
  • Population Health Partners, L.P. is a private equity firm committed to building great companies around important late-stage therapeutics and solving the health and economic challenges presented by prevalent diseases.

Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic

Retrieved on: 
Wednesday, October 19, 2022

Founded in 2015, Orionis has since developed its proprietary technology platforms, grown a deep pipeline and cemented a drug discovery deal with Novartis.

Key Points: 
  • Founded in 2015, Orionis has since developed its proprietary technology platforms, grown a deep pipeline and cemented a drug discovery deal with Novartis.
  • This latest financing round provides the company with additional capital for R&D expansion, pipeline growth and advancement of its lead cancer immunotherapy programs into clinical trials.
  • Existing and new investors participated in the round, including Cormorant Asset Management, Novartis and a series of high-caliber investment funds.
  • In addition, we are pleased to welcome industry veteran Bihua Chen to our Board as we enter this next stage of growth.

Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2

Retrieved on: 
Wednesday, October 19, 2022

Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.

Key Points: 
  • Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
  • A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/748805907 or via the webcast link on the Investor Relations page of the Companys website , https://ir.castlebiosciences.com/overview/default.aspx .
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221019005130/en/

Tempo Bioscience Expands Patient-Relevant Blood-Brain-Barrier Models for Drug Development

Retrieved on: 
Wednesday, October 19, 2022

These new products add to the already-existing Tempo Bioscience product lines and expand the TempoStemBank Disease Model offerings.

Key Points: 
  • These new products add to the already-existing Tempo Bioscience product lines and expand the TempoStemBank Disease Model offerings.
  • Tempo Bioscience is the sole manufacturer of human iPSC-derived cell types that are engineered using non-viral, nucleic-acids-free, serum-free, and feeder-free technologies.
  • Tempos patient-relevant cell models aim to improve drug efficacy evaluations and safety assessments during drug development.
  • About Tempo Bioscience, Inc.: Tempo is a technology development focused biotechnology company based in San Francisco, California.

Transcat Announces Second Quarter Fiscal Year 2023 Conference Call and Webcast

Retrieved on: 
Tuesday, October 18, 2022

The Company will host a conference call and webcast to review the financial and operating results for the period and discuss its corporate strategy and outlook.

Key Points: 
  • The Company will host a conference call and webcast to review the financial and operating results for the period and discuss its corporate strategy and outlook.
  • Webcast and accompanying slide presentation: https://www.transcat.com/investor-relations
    A telephonic replay will be available from 2:00 p.m.
  • To listen to the archived call, dial (412) 317-6671 and enter conference ID number 13733840 or access the webcast replay at https://www.transcat.com/investor-relations , where a transcript will be posted once available.
  • Transcat, Inc. is a leading provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services.

Vyripharm Enterprises Inc and ABB, Inc. collaborate on the design and development of Automation and Robotics to advance Testing Laboratory Platform for Public Health and Public Safety

Retrieved on: 
Monday, October 17, 2022

ABB will provide state of the art automation software and robotics to demonstrate the operational function of the integrative platforms.

Key Points: 
  • ABB will provide state of the art automation software and robotics to demonstrate the operational function of the integrative platforms.
  • The collaborative effort between ABB and VEI, brings this concept to reality in the biopharma industry, advancing public health care and safety.
  • ABB Life Sciences and Healthcare Solutions is the leader in the integration of automation across the Life Sciences supply chain.
  • Our aim is to ensure the security of agribiopharmaceuticals through our commitment to public health and safety.